Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry
Objective. In this study, we sought to compare the efficacy and safety of the Xience Prime/Xience V/Promus EES and Biomatrix/Biomatrix Flex/Nobori BES with resolute integrity/resolute ZES using the grand drug-eluting stent (Grand-DES) registry. Background. Currently, new-generation drug-eluting sten...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Interventional Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2020/3872704 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832567426895577088 |
|---|---|
| author | You-Jeong Ki Kyung Woo Park Jeehoon Kang Chee-Hoon Kim Jung-Kyu Han Han-Mo Yang Hyun-Jae Kang Bon-Kwon Koo Hyo-Soo Kim |
| author_facet | You-Jeong Ki Kyung Woo Park Jeehoon Kang Chee-Hoon Kim Jung-Kyu Han Han-Mo Yang Hyun-Jae Kang Bon-Kwon Koo Hyo-Soo Kim |
| author_sort | You-Jeong Ki |
| collection | DOAJ |
| description | Objective. In this study, we sought to compare the efficacy and safety of the Xience Prime/Xience V/Promus EES and Biomatrix/Biomatrix Flex/Nobori BES with resolute integrity/resolute ZES using the grand drug-eluting stent (Grand-DES) registry. Background. Currently, new-generation drug-eluting stents (DESs) are used as the standard of care in patients undergoing percutaneous coronary intervention. No study has simultaneously compared everolimus-eluting stent (EES), biolimus-eluting stent (BES), and zotarolimus-eluting stent (ZES). Methods. Stent-related composite outcomes (target lesion failure) and patient-related composite outcomes were compared in crude and propensity score-matched analysis. Results. Of the 17,286 patients in the Grand-DES group, 5,137, 2,970, and 4,990 patients in the EES, BES, and ZES groups completed a three-year follow-up. In the propensity score-matched cohort, the stent-related outcome (EES vs. BES vs. ZES; 5.9% vs. 6.7% vs. 7.1%, P=0.226) and patient-related outcomes (12.7% vs. 13.5% vs. 14.3%, P=0.232) were similar among the three groups, at 3 years. The rate of definite or probable stent thrombosis (0.6% vs. 0.8% vs. 0.5%, P=0.549) was similar. In the multivariate analysis, chronic kidney disease was the strongest predictor of stent thrombosis (adjusted hazard ratio 3.178; 95% confidence interval 1.621–6.229; P<0.001). Conclusions. In this robust real-world registry with unrestricted use of EES, BES, and ZES, the three stent groups showed comparable safety and efficacy at the 3-year follow-up. |
| format | Article |
| id | doaj-art-16f51024287e44f38a9b342d042ea04e |
| institution | Kabale University |
| issn | 0896-4327 1540-8183 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Interventional Cardiology |
| spelling | doaj-art-16f51024287e44f38a9b342d042ea04e2025-02-03T01:01:31ZengWileyJournal of Interventional Cardiology0896-43271540-81832020-01-01202010.1155/2020/38727043872704Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES RegistryYou-Jeong Ki0Kyung Woo Park1Jeehoon Kang2Chee-Hoon Kim3Jung-Kyu Han4Han-Mo Yang5Hyun-Jae Kang6Bon-Kwon Koo7Hyo-Soo Kim8Department of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of KoreaDepartment of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of KoreaDepartment of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of KoreaDepartment of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of KoreaDepartment of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of KoreaDepartment of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of KoreaDepartment of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of KoreaDepartment of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of KoreaDepartment of Internal Medicine and Cardiovascular Center, Seoul National University Hospital, Seoul 03080, Republic of KoreaObjective. In this study, we sought to compare the efficacy and safety of the Xience Prime/Xience V/Promus EES and Biomatrix/Biomatrix Flex/Nobori BES with resolute integrity/resolute ZES using the grand drug-eluting stent (Grand-DES) registry. Background. Currently, new-generation drug-eluting stents (DESs) are used as the standard of care in patients undergoing percutaneous coronary intervention. No study has simultaneously compared everolimus-eluting stent (EES), biolimus-eluting stent (BES), and zotarolimus-eluting stent (ZES). Methods. Stent-related composite outcomes (target lesion failure) and patient-related composite outcomes were compared in crude and propensity score-matched analysis. Results. Of the 17,286 patients in the Grand-DES group, 5,137, 2,970, and 4,990 patients in the EES, BES, and ZES groups completed a three-year follow-up. In the propensity score-matched cohort, the stent-related outcome (EES vs. BES vs. ZES; 5.9% vs. 6.7% vs. 7.1%, P=0.226) and patient-related outcomes (12.7% vs. 13.5% vs. 14.3%, P=0.232) were similar among the three groups, at 3 years. The rate of definite or probable stent thrombosis (0.6% vs. 0.8% vs. 0.5%, P=0.549) was similar. In the multivariate analysis, chronic kidney disease was the strongest predictor of stent thrombosis (adjusted hazard ratio 3.178; 95% confidence interval 1.621–6.229; P<0.001). Conclusions. In this robust real-world registry with unrestricted use of EES, BES, and ZES, the three stent groups showed comparable safety and efficacy at the 3-year follow-up.http://dx.doi.org/10.1155/2020/3872704 |
| spellingShingle | You-Jeong Ki Kyung Woo Park Jeehoon Kang Chee-Hoon Kim Jung-Kyu Han Han-Mo Yang Hyun-Jae Kang Bon-Kwon Koo Hyo-Soo Kim Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry Journal of Interventional Cardiology |
| title | Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry |
| title_full | Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry |
| title_fullStr | Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry |
| title_full_unstemmed | Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry |
| title_short | Safety and Efficacy of Second-Generation Drug-Eluting Stents in Real-World Practice: Insights from the Multicenter Grand-DES Registry |
| title_sort | safety and efficacy of second generation drug eluting stents in real world practice insights from the multicenter grand des registry |
| url | http://dx.doi.org/10.1155/2020/3872704 |
| work_keys_str_mv | AT youjeongki safetyandefficacyofsecondgenerationdrugelutingstentsinrealworldpracticeinsightsfromthemulticentergranddesregistry AT kyungwoopark safetyandefficacyofsecondgenerationdrugelutingstentsinrealworldpracticeinsightsfromthemulticentergranddesregistry AT jeehoonkang safetyandefficacyofsecondgenerationdrugelutingstentsinrealworldpracticeinsightsfromthemulticentergranddesregistry AT cheehoonkim safetyandefficacyofsecondgenerationdrugelutingstentsinrealworldpracticeinsightsfromthemulticentergranddesregistry AT jungkyuhan safetyandefficacyofsecondgenerationdrugelutingstentsinrealworldpracticeinsightsfromthemulticentergranddesregistry AT hanmoyang safetyandefficacyofsecondgenerationdrugelutingstentsinrealworldpracticeinsightsfromthemulticentergranddesregistry AT hyunjaekang safetyandefficacyofsecondgenerationdrugelutingstentsinrealworldpracticeinsightsfromthemulticentergranddesregistry AT bonkwonkoo safetyandefficacyofsecondgenerationdrugelutingstentsinrealworldpracticeinsightsfromthemulticentergranddesregistry AT hyosookim safetyandefficacyofsecondgenerationdrugelutingstentsinrealworldpracticeinsightsfromthemulticentergranddesregistry |